Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy

CHEN Yin-Bo; HAO Yun-Peng; HAO Xiao-Sheng; LIANG Dong

doi:10.7499/j.issn.1008-8830.2013.05.005

PDF(933 KB)

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (5) : 340-342. DOI: 10.7499/j.issn.1008-8830.2013.05.005

CLINICAL RESEARCH

Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy

CHEN Yin-Bo, HAO Yun-Peng, HAO Xiao-Sheng, LIANG Dong

Author information +

History +

Abstract

OBJECTIVE: To investigate the clinical efficacy and safety of oxcarbazepine (OXC) suspension in children with focal epilepsy. METHODS: A total of 118 children aged 2-14 years, who were newly diagnosed with focal epilepsy between October 2009 and December 2011, were randomly divided into experimental group (n=60) and control group (n=58). The experimental group was treated with an orally suspension of OXC and the control group was orally administered with carbamazepine (CBZ) tablets. The two treatment regimens were compared in terms of clinical efficacy and safety. RESULTS: After 13 and 26 weeks of treatment, the experimental group had response rates of 75% and 72% respectively and seizure-free rates of 53% and 50%, and the control group had response rates of 71% and 66% and seizure-free rates of 50% and 43% respectively. There were no significant differences in the clinical efficacy between the two groups (P>0.05). After 26 weeks of treatment, the adverse event rates of the experimental and control groups were 18% and 40% respectively, with a significant difference between the two groups (P<0.05). CONCLUSIONS: OXC suspension has a comparable clinical efficacy to that of CBZ tablets in children aged 2-14 years who are newly diagnosed with focal epilepsy, but OXC suspension causes fewer adverse events and has higher safety.

Key words

Oxcarbazepine suspension / Focal epilepsy / Efficacy / Safety / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CHEN Yin-Bo, HAO Yun-Peng, HAO Xiao-Sheng, LIANG Dong. Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(5): 340-342 https://doi.org/10.7499/j.issn.1008-8830.2013.05.005

References

［1］梁慧芬. MIMS 中国药品手册年刊（中国版）2011/2012［M］. 第15版.北京：美迪医讯亚太有限公司，2011: 712-715.

［2］中华医学会神经病学会脑电图与癫癎学组.抗癫癎药物应用专家共识［J］.中华神经科杂志, 2011, 44(1): 56-65.

［3］朱国行, 吴洵映,虞培敏,王晋扬,章悦,洪震.新诊断癫癎患者的规范化药物治疗［J］. 中华神经科杂志, 2011, 44(1): 6-9.

［4］肖波,刘献增,龙小艳，王晓飞主译.癫癎治疗学［M］.第2版.北京:人民卫生出版社, 2010: 384-391.

［5］Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use［J］. Epilepsy Behav, 2000, 1(6): 396-405.

［6］黄铁栓，朱金兰，李冰，胡雁，廖建湘.抗癫癎药物加重儿童癫癎发作的临床研究［J］. 中国当代儿科杂志, 2004, 6(5): 401-402.

［7］陈银波，王江涛，王丽君，梁东.奥卡西平混悬液单药治疗2～4岁新诊断的部分性癫癎患儿的临床观察［J］. 中华神经科杂志, 2012， 45(10): 730-733.

［8］Bourgeois BF, D′Souza J. Longterm safety and tolerability of oxcarbazepine in children: a review of clinical experience［J］. Epilepsy Behav, 2005, 7(3): 375-382.

［9］Franzoni E, Garone C, Sarajlija J, Gualandi S, Malaspina E, Cecconi I, et al. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report［J］. Seizure, 2006, 15(5): 292-298.

［10］Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG,Valencia I, et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience［J］. Pediatr Neurol, 2006, 35(4): 235-239.

［11］Rey E, Bulteau C, Motte J, Tran A, Sturm Y, D’Souza J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy［J］. Clin Pharmacol, 2004, 44 (11): 1290-1300.